When the DREAM is gone: From basic science to future prospectives in pain management and beyond

Expert Opinion on Therapeutic Targets

Volumn 7, Issue 2, 2003, Pages 249-263

  Cheng, Hai Ying ^a   Penninger, Josef M ^b  

^a University Health Network   (Canada)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

Calcium (Ca2+); Calsenilin (CS); cAMP; DREAM; Gene expression; KChIP3; Pain modulation; Presenilin (PS); Prodynorphin; Transcription factor

Indexed keywords

CALCIUM BINDING PROTEIN; CALSENILIN; CANNABINOID; COMPLEMENTARY DNA; DIZOCILPINE; DOWNSTREAM REGULATORY ELEMENT ANTAGONISTIC MODULATOR; HERBACEOUS AGENT; JANUS KINASE; MORPHINE; NALOXONE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL STIMULATING AGENT; PRESENILIN 1; PRESENILIN 2; PRODYNORPHIN; PROTEIN KINASE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; CHRONIC PAIN; DIABETIC NEUROPATHY; DRUG DEPENDENCE; DRUG SENSITIVITY; DRUG TOLERANCE; GASTROINTESTINAL DISEASE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; IN VITRO STUDY; MOLECULAR GENETICS; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PLEIOTROPY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RESPIRATION DEPRESSION; REVIEW; TRANSCRIPTION REGULATION;

AMINO ACID SEQUENCE; ANALGESICS; ANIMALS; DOGS; DRUG EVALUATION, PRECLINICAL; ENKEPHALINS; FORECASTING; HUMANS; KV CHANNEL-INTERACTING PROTEINS; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PAIN; PAIN INSENSITIVITY, CONGENITAL; POTASSIUM CHANNELS; PRESENILIN-2; PROTEIN PRECURSORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC;

EID: 0037399166     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/eott.7.2.249.23781     Document Type: Review

References (119)

1. BERRIDGE MJ, LIPP P, BOOTMAN MD: The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell. Biol. (2000) 1:11-21.
2. 2+-binding proteins. Biochem. J. (2001) 353:1-12.
3. BUXBAUM JD, CHOI E-K, LUO Y et al.: Calsenilin: a calcium-binding protein that interacts with the presenilins and regulates the levels of a presenilin fragment. Nat. Med. (1998) 4:1177-1181.
4. 2+-regulated transcriptional repressor. Nature (1999) 398:80-84.
5. AN WF, BOWLBY MR, BETTY M et al.: Modulation of A-type potassium channels by a family of calcium sensors. Nature (2000) 403:553-556.
6. CHENG HY, PITCHER GM, LAVIOLETTE SR et al.: DREAM is a critical transcriptional repressor for pain modulation. Cell (2002) 108:31-43.
7. SCHELLENBERG GD, BIRD TD, WIJSMAN EM et al.: Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science (1992) 258:668-671.
8. SHERRINGTON R, ROGAEV EI, LIANG Y et al.: Cloning of a novel gene bearing missense mutations in early onset familial Alzheimer disease. Nature (1995) 375:754-760.
9. LEVY-LAHAD E, WASCO W, POORKAJ P et al.: Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science (1995) 269:973-977.
10. KOVACS DM, FAUSETT HJ, PAGE KJ et al.: Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat. Med. (1996) 2:224-229.
11. LI YM, XU M, LAI MT et al.: Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature (2000) 405:689-694.
12. ZHANG Z, NADEAU P, SONG W et al.: Presenilins are required for gamma-secretase cleavage of β-APP and transmembrane cleavage of Notch-1. Nat. Cell. Biol. (2000) 2:463-465.
13. WOLOZIN B, IWASAKI K, VITO P et al.: Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science (1996) 274:1710-1713.
14. 2+)-binding protein ALG-2 and Alzheimer's disease gene ALG-3. Science (1996) 271:521-525.
15. KIM TW, PETTINGELL WH, JUNG YK, KOVACS DM, TANZI RE: Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. Science (1997) 277:373-376.
16. GUO Q, SOPHER BL, FURUKAWA K et al.: Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid β-peptide: involvement of calcium and oxyradicals. J. Neurosci. (1997) 17:4212-4222.
17. KELLER JN, GUO Q, HOLTSBERG FW, BRUCE-KELLER AJ, MATTSON MP: Increased sensitivity to mitochondrial toxin-induced apoptosis in neural cells expressing mutant presenilin-1 is linked to perturbed calcium homeostasis and enhanced oxyradical production. J. Neurosci. (1998) 18:4439-4450.
18. VACCARINO AL, KASTIN AJ: Endogenous opiates: 2000. Peptides (2001) 22:2257-2328.
19. DOUGLASS J, MCKINZIE AA, POLLOCK KM: Identification of multiple DNA elements regulating basal and protein kinase A-induced transcriptional expression of the rat prodynorphin gene. Mol. Endocrinol. (1994) 8:333-344.
20. NARANJO JR, MELLSTROM B, ACHAVAL M, SASSONE-CORSI P: Molecular pathways of pain: Fos/Jun-mediated activation of a noncanonical AP-1 site in the prodynorphin gene. Neuron (1991) 6:607-617.
21. MCMURRAY CT, DEVI L, CALAVETTA L, DOUGLASS JO: Regulated expression of the prodynorphin gene in the R2C Leydig tumor cell line. Endocrinology (1989) 124:49-59.
22. CARRION AM, MELLSTROM B, LUCKMAN SM, NARANJO JR: Stimulus-specific hierarchy of enhancer elements within the rat prodynorphin promoter. J. Neurochem. (1998) 70:914-921.
23. MESSERSMITH DJ, KIM DJ, IADAROLA MJ: Transcription factor regulation of prodynorphin gene expression following rat hindpaw inflammation. Brain Res. Mol. Brain Res. (1998) 53:260-269.
24. COLLINS-HICOK J, LIN L, SPIRO C et al.: Induction of the rat prodynorphin gene through Gs-coupled receptors may involve phosphorylation-dependent derepression and activation. Mol. Cell. Biol. (1994) 14:2837-2848.
25. CARRION AM, MELLSTROM B, NARANJO JR: Protein kinase A-dependent derepression of the human prodynorphin gene via differential binding to an intragenic silencer element. Mol. Cell. Biol. (1998) 12:6921-6929.
26. + current mediated by the Kv4 channel regulates the generation of action potential in developing cerebellar granule cells. J. Neurosci. (2000) 20:4145-4155.
27. JOHNS DC, NUSS HB, MARBAN E: Suppression of neuronal and cardiac transient outward currents by viral gene transfer of dominant-negative Kv4.2 constructs. J. Biol. Chem. (1997) 272:31598-31603.
28. + channel regulation of signal propagation in dendrites of hippocampal pyramidal neurons. Nature (1997) 387:869-875.
29. + current modulated by arachidonic acid regulates synaptic integration and threshold for LTP induction in hippocampal pyramidal cells. Proc. Natl. Acad. Sci. USA (2002) 99:10144-10149.
30. + channel in ventricular muscle. A molecular correlate for the transient outward current. Circ. Res. (1996) 79:659-668.
31. HOPPE UC, MARBAN E, JOHNS DC: Molecular dissection of cardiac repolarization by in vivo Kv4.3 gene transfer. J. Clin. Invest. (2000) 105:1077-1084.
32. YAN GX, ANTZELEVITCH C: Cellular basis for the electrocardiographic J wave. Circulation (1996) 93:372-379.
33. NABAUER M, BEUCKELMANN DJ, UBERFUHR P, STEINBECK G: Regional differences in current density and rate-dependent properties of the transient outward current in subepicardial and subendocardial myocytes of human left ventricle. Circulation (1996) 93:168-177.
34. ROSATI B, PAN Z, LYPEN S et al.: Regulation of KChIP2 potassium channel β subunit gene expression underlies the gradient of transient outward current in canine and human ventricle. J. Physiol. (2001) 533:119-125.
35. SPREAFICO F, BARSKI JJ, FARINA C, MEYER M: Mouse DREAM/calsenilin/ KChIP3: gene structure, coding potential, and expression. Mol. Cell. Neurosci. (2001) 17:1-16.
36. 2+)-binding protein. J. Biol. Chem. (1995) 270:15571-15575.
37. KOBAYASHI M, AITA N, HAYASHI S, OKADA K, OHTA T, HIROSE S: DNA supercoiling factor localizes to puffs on polytene chromosomes in Drosophila melanogaster. Mol. Cell. Biol. (1998) 18:6737-6744.
38. KOBAYASHI M, HIROSE S: Functional dissection of DNA supercoiling factor: EF-hand domains and C-terminal HDEF motif are essential for its activity. Genes Cells. (1999) 4:33-40.
39. SCHRADER LA, ANDERSON AE, MAYNE A et al.: Modulation of Kv4.2 current by KChIP3 and PKA activation. 31st Annual Meeting of the Society for Neuroscience, San Diego, USA, Vol. 27. Abstract.
40. CHOI EK, MILLER JS, ZAIDI NF et al.: Functional role of post-translational modification of calsenilin in Alzheimer's disease. 31st Annual Meeting of the Society for Neuroscience, San Diego, CA, Volume 27. Abstract.
41. TAKIMOTO K, YANG EK, CONFORTI L: Palmitoylation of KChIP splicing variants is required for efficient cell surface expression of Kv4.3 channels. J. Biol. Chem. (2002) 277:26904-26911.
42. SANZ C, MELLSTROM B, LINK WA, NARANJO JR, FERNANDEZ-LUNA JL: Interleukin 3-dependent activation of DREAM is involved in transcriptional silencing of the apoptotic hrk gene in hematopoietic progenitor cells. EMBO J. (2001) 20:2286-2292.
43. OSAWA M, TONG KI, LILLIEHOOK C et al.: Calcium-regulated DNA binding and oligomerization of the neuronal calcium-sensing protein, calsenilin/DREAM/ KChIP3. J. Biol. Chem. (2001) 276:41005-41013.
44. CRAIG TA, BENSON LM, VENYAMINOV SY et al.: The metal-binding properties of DREAM: evidence for calcium-mediated changes in DREAM structure. J. Biol. Chem. (2002) 277:10955-10966.
45. IKURA M, OSAWA M, AMES JB: The role of calcium-binding proteins in the control of transcription: structure to function. Bioessays (2002) 24:625-636.
46. LEDO F, LINK WA, CARRION AM, ECHEVERRIA V, MELLSTROM B, NARANJO JR: The DREAM-DRE interaction: key nucleotides and dominant negative mutants. Biochim. Biophys. Acta. (2000) 1498:162-168.
47. MESSERSMITH DJ, GU J, DUBNER R, DOUGLASS J, IADAROLA MJ: Basal and inducible transcriptional activity of an upstream AP-1/CRE element (DYNCRE3) in the prodynorphin promoter. Mol. Cell. Neurosci. (1994) 5:238-245.
48. LEDO F, CARRION AM, LINK WA, MELLSTROM B, NARANJO JR: DREAM-αCREM interaction via leucine-charged domains derepresses downstream regulatory element-dependent transcription. Mol. Cell. Biol. (2000) 20:9120-9126.
49. DE CESARE D, FIMIA GM, SASSONE-CORSI P: Signaling routes to CREM and CREB: plasticity in transcriptional activation. Trends Biochem. Sci. (1999) 24:281-285.
50. DELMAS V, LAOIDE BM, MASQUILIER D, DE GROOT RP, FOULKES NS, SASSONE-CORSI P: Alternative usage of initiation codons in mRNA encoding the cAMP-responsive-element modulator generates regulators with opposite functions. Proc. Natl. Acad. Sci. USA (1992) 89:4226-4230.
51. MOLINA CA, FOULKES NS, LALLI E, SASSONE-CORSI P: Inducibility and negative autoregulation of CREM: an alternative promoter directs the expression of ICER, an early response repressor. Cell (1993) 75:875-886.
52. HEERY DM, KALKHOVEN E, HOARE S, PARKER MG: A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature (1997) 387:733-736.
53. DE GROOT RP, BALLOU LM, SASSONE-CORSI P: Positive regulation of the cAMP-responsive activator CREM by the p70 S6 kinase: an alternative route to mitogen-induced gene expression. Cell (1994) 79:81-91.
54. 2+-dependent block of CREB-CBP transcription by repressor DREAM. EMBO J. (2002) 21:4583-4592.
55. MAYR B, MONTMINY M: Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat. Rev. Mol. Cell. Biol. (2001) 2:599-609.
56. BRUNET A, DATTA SR, GREENBERG ME: Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr. Opin. Neurobiol. (2001) 11:297-305.
57. SANZ C, BENITO A, INOHARA N, EKHTERAE D, NUNEZ G, FERNANDEZ-LUNA JL: Specific and rapid induction of the proapoptotic protein Hrk after growth factor withdrawal in hematopoietic progenitor cells. Blood (2000) 95:2742-2747.
58. CODERRE TJ, VACCARINO AL, MELZACK R: Central nervous system plasticity in the tonic pain response to subcutaneous formalin injection. Brain Res. (1990) 535:155-158.
59. ABBADIE C, TAYLOR BK, PETERSON MA, BASBAUM AI: Differential contribution of the two phases of the formalin test to the pattern of c-fos expression in the rat spinal cord: studies with remifentanil and lidocaine. Pain (1997) 69:101-110.
60. SIMONIN F, VALVERDE O, SMADJA C et al.: Disruption of the κ-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective κ-agonist U-50,488H and attenuates morphine withdrawal. EMBO J. (1998) 17:886-897.
61. BURTON MB, GEBHART GF: Effects of κ-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation. J. Pharmacol. Exp. Ther. (1998) 285:707-715.
62. SANDNER-KIESLING A, PAN HL et al.: Effect of κ opioid agonists on visceral nociception induced by uterine cervical distension in rats. Pain (2002) 96:13-22.
63. ARNER S, MEYERSON BA: Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain (1988) 33:11-23.
64. KUPERS RC, KONINGS H, ADRIAENSEN H, GYBELS JM: Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. Pain (1991) 47:5-12.
65. JADAD AR, CARROLL D, GLYNN CJ, MOORE RA, MCQUAY HJ: Morphine responsiveness of chronic pain: double-blind randomised crossover study with patient-controlled analgesia. Lancet (1992) 339:1367-1371.
66. PORTENOY RK, FOLEY KM, INTURRISI CE: The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain (1990) 43:273-286.
67. BENEDETTI F, VIGHETTI S, AMANZIO M et al.: Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain. Pain (1998) 74:205-211.
68. MOSCONI T, KRUGER L: Fixed-diameter polyethylene cuffs applied to the rat sciatic nerve induce a painful neuropathy: ultrastructural morphometric analysis of axonal alterations. Pain (1996) 64:37-57.
69. YAMAMOTO T, OHTORI S, CHIBA T: Effects of pre-emptively administered nociceptin on the development of thermal hyperalgesia induced by two models of experimental mononeuropathy in the rat. Brain Res. (2000) 871:192-200.
70. SAVAGE SR: Opioid use in the management of chronic pain. Med. Clin. North. Am. (1999) 83:761-786.
71. BENNETT J, WREN KR, HAAS R: Opioid use during the perianesthesia period: nursing implications. J. Perianesth. Nurs. (2001) 16:255-258.
72. DAY R, LAZURE C, BASAK A et al.: Prodynorphin processing by proprotein convertase 2. Cleavage at single basic residues and enhanced processing in the presence of carboxypeptidase activity. J. Biol. Chem. (1998) 273:829-836.
73. BERMAN Y, MZHAVIA N, POLONSKAIA A et al.: Defective prodynorphin processing in mice lacking prohormone convertase PC2. J. Neurochem. (2000) 75:1763-1770.
74. SILBERRING J, CASTELLO ME, NYBERG F: Characterization of dynorphin A-converting enzyme in human spinal cord. An endoprotease related to a distinct conversion pathway for the opioid heptadecapeptide? J. Biol. Chem. (1992) 267:21324-21328.
75. CABOT PJ, CARTER L, SCHAFER M, STEIN C: Methionine-enkephalin and dynorphin A-release from immune cells and control of inflammatory pain. Pain (2001) 93:207-212.
76. DAWSON-BASOA M, GINTZLER AR: Gestational and ovarian sex steroid antinociception: synergy between spinal κ and δ opioid systems. Brain Res. (1998) 794:61-67.
77. GUPTA DS, KELSON AB, POLGAR WE, TOLL L, SZUCS M, GINTZLER AR: Ovarian sex steroid-dependent plasticity of nociceptin/orphanin FQ and opioid modulation of spinal dynorphin release. J. Pharmacol. Exp. Ther. (2001) 298:1213-1220.
78. MEDINA VM, DAWSON-BASOA ME, GINTZLER AR: 17β-estradiol and progesterone positively modulate spinal cord dynorphin: relevance to the analgesia of pregnancy. Neuroendocrinology (1993) 58:310-315.
79. VARSHNEY C, RIVERA M, GINTZLER AR: Modulation of prohormone convertase 2 in spinal cord during gestation and hormone-simulated pregnancy. Neuroendocrinology (1999) 70:268-279.
80. XIN L, GELLER EB, ADLER MW: Body temperature and analgesic effects of selective mu microdialyzed into rat brain. J. Pharmacol. Exp. Ther. (1997) 281:499-507.
81. PASTERNAK KR, ROSSI GC, ZUCKERMAN A, PASTERNAK GW: Antisense mapping KOR-1: evidence for multiple κ analgesic mechanisms. Brain Res. (1999) 826:289-292.
82. HAN JS, CHEN XH, SUN SL et al.: Effect of low- and high-frequency TENS on Met-enkephalin-Arg-Phe and dynorphin A immunoreactivity in human lumbar CSF. Pain (1991) 47:295-298.
83. HAN JS, XIE GX: Dynorphin: important mediator for electroacupuncture analgesia in the spinal cord of the rabbit. Pain (1984) 18:367-376.
84. OMIYA Y, GOTO K, SUZUKI Y, ISHIGE A, KOMATSU Y: Analgesia-producing mechanism of processed Aconiti tuber: role of dynorphin, an endogenous κ-opioid ligand, in the rodent spinal cord. Jpn. J. Pharmacol. (1999) 79:295-301.
85. SUZUKI Y, GOTO K ISHIGE A, KOMATSU Y, KAMEI J: Antinociceptive effect of Gosha-jinki-gan, a Kampo medicine, in streptozotocin-induced diabetic mice. Jpn. J. Pharmacol (1999) 79:169-175.
86. HOUSER SJ, EADS M, EMBREY JR, WELCH SP: Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Δ(9)-THC and anandamide. Brain Res. (2000) 857:337-342.
87. PUGH G Jr, SMITH PB, DOMBROWSKI DS, WELCH SP: The role of endogenous opioids in enhancing the antinociception produced by the combination of δ9-tetrahydrocannabinol and morphine in the spinal cord. J. Pharmacol. Exp. Ther. (1996) 279:608-616.
88. PUGH G JR, ABOOD ME, WELCH SP: Antisense oligodeoxynucleotides to the κ-1 receptor block the antinociceptive effects of Δ9-THC in the spinal cord. Brain Res. (1995) 689:157-158.
89. DRAISCI G, KAJANDER KC, DUBNER R, BENNETT GJ, IADAROLA MJ: Up-regulation of opioid gene expression in spinal cord evoked by experimental nerve injuries and inflammation. Brain Res. (1991) 560:186-192.
90. LAUGHLIN TM, LARSON AA, WILCOX GL: Mechanisms of induction of persistent nociception by dynorphin. J. Pharmacol. Exp. Ther. (2001) 299:6-11.
91. TANG Q, GANDHOKE R, BURRITT A, HRUBY VJ, PORRECA F, LAI J: High-affinity interaction of (destyrosyl) dynorphin A(2-17) with NMDA receptors. J. Pharmacol. Exp. Ther. (1999) 291:760-765.
92. LAUGHLIN TM, VANDERAH TW, LASHBROOK J et al.: Spinally administered dynorphin A produces long-lasting allodynia: involvement of NMDA but not opioid receptors. Pain (1997) 72:253-260.
93. SHARIFI N, DIEHL N, YASWEN L, BRENNAN MB, HOCHGESCHWENDER U: Generation of dynorphin knockout mice. Brain Res. Mol. Brain Res. (2001) 86:70-75.
94. WANG Z, GARDELL LR, OSSIPOV MH et al.: Pronociceptive actions of dynorphin maintain chronic neuropathic pain. J. Neurosci. (2001) 21:1779-1786.
95. GAUMANN DM, GRABOW TS, YAKSH TL, CASEY SJ, RODRIGUEZ M: Intrathecal somatostatin, somatostatin analogs, substance P analog and dynorphin A cause comparable neurotoxicity in rats. Neuroscience (1990) 39:761-774.
96. TAYLOR JS, MORCUENDE S, NARANJO JR: Molecular pain of pain: "knockdown" of the prodynorphin gene reveals an involvement in antinociception. In: Molecular Neurobiology of Pain, Progress in Pain Research and Management (Vol. 9). Borsook D (Ed.), IASP Press, Seattle (1997):201-218.
97. RILEY RC, ZHAO, ZQ, DUGGAN AW: Spinal release of immunoreactive dynorphin A(1-8) with the development of peripheral inflammation in the rat. Brain Res. (1996) 710:131-142.
98. 2+ concentration in cultured rat spinal neurons. Eur. J. Pharmacol. (1998) 342:325-332.
99. MOROHASHI Y, HATANO N, OHYA S et al.: Molecular cloning and characterization of CALP/KChIP4, a novel EF-hand protein interacting with presenilin 2 and voltage-gated potassium channel subunit Kv4. J. Biol. Chem. (2002) 277:14965-14975.
100. +) currents in the mammalian myocardium by neuronal calcium sensor-1. J. Biol. Chem. (2002) 277:26436-26443.
101. LILLIEHOOK C, CHAN S, CHOI EK et al.: Calsenilin enhances apoptosis by altering endoplasmic reticulum calcium signaling. Mol. Cell. Neurosci. (2002) 19:552-559.
102. JO DG, KIM MJ, CHOI YH et al.: Pro-apoptotic function of calsenilin/ DREAM/KChIP3. FASEB J. (2001) 15:589-591.
103. LEISSRING MA, YAMASAKI TR, WASCO W, BUXBAUM JD, PARKER I, LAFERLA FM: Calsenilin reverses presenilin-mediated enhancement of calcium signaling. Proc. Natl. Acad. Sci. USA (2000) 97:8590-8593.
104. MATTSON MP, LAFERLA FM, CHAN SL, LEISSRING MA, SHEPEL PN, GEIGER JD: Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci. (2000) 23:222-229.
105. ESLER WP, KIMBERLY WT, OSTASZEWSKI BL et al.: Activity-dependent isolation of the presenilin- gamma-secretase complex reveals nicastrin and a gamma substrate. Proc. Natl. Acad. Sci. USA (2002) 99:2720-2725.
106. HSIAO, K, CHAPMAN P, NILSEN S et al.: Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science (1996) 274:99-102.
107. CHUI DH, TANAHASHI H, OZAWA K et al.: Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat. Med. (1999) 5:560-564.
108. KUO HC, CHENG CF, CLARK RB et al.: A defect in the Kv channel-interacting protein 2 (KChIP2) gene leads to a complete loss of I(to) and confers susceptibility to ventricular tachycardia. Cell (2001) 107:801-813.
109. DESCHENES I, DISILVESTRE D, JUANG GJ, WU RC, AN WF, TOMASELLI GF: Regulation of Kv4.3 current by KChIP2 splice variants: a component of native cardiac I(to)? Circulation (2002) 106:423-429.
110. ZIMPRICH A, KRAUS J, WOLTJE M, MAYER P, RAUCH E, HOLLT V: An allelic variation in the human prodynorphin gene promoter alters stimulus-induced expression. J. Neurochem. (2000) 74:472-477.
111. CHEN AC, LAFORGE KS et al.: Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse. Am. J. Med. Genet. (2002) 114:429-435.
112. STOGMANN E, ZIMPRICH A, BAUMGARTNER C, AULL-WATSCHINGER S, HOLLT V, ZIMPRICH F: A functional polymorphism in the prodynorphin gene promotor is associated with temporal lobe epilepsy. Ann. Neurol. (2002) 51:260-263.
113. CARLEZON WA JR, THOME J, OLSON VG et al.: Regulation of cocaine reward by CREB. Science (1998) 282:2272-2275.
114. HURD YL: Subjects with major depression or bipolar disorder show reduction of prodynorphin mRNA expression in discrete nuclei of the amygdaloid complex. Mol. Psychiatry (2002) 7:75-81.
115. LIN CR, YANG LC, LEE TH et al.: Electroporation-mediated pain-killer gene therapy for mononeuropathic rats. Gene Ther. (2002) 9:1247-1253.
116. WILSON SP, YEOMANS DC, BENDER MA, LU Y, GOINS WF, GLORIOSO JC: Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc. Natl. Acad. Sci. USA (1999) 96:3211-3216.
117. BRIDGES D, THOMPSON SW, RICE AS: Mechanisms of neuropathic pain. Br. J. Anaesth. (2001) 87:12-26.
118. CHENG HYM, PENNINGER JM: Transcriptional mechanisms underlying neuropathic pain: DREAM, transcription factors and future pain management? Expert Rev. Neurotherapeutics (2002) 2:89-101.
119. MANSOUR A, HOVERSTEN MT, TAYLOR LP, WATSON SJ, AKIL H: The cloned μ, δ and κ receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain Res. (1995)